Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.
By J. Baselga, K. Gelmon, S. Verma, A. Wardley, P. Conte, D. Miles, G. Bianchi, J. Cortés, V. Mcnally, G. Ross and 2 more. Journal of Clinical Oncology, 2010
660 citations recorded by the source corpus.
Subfields: Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/3f822c91a736961bdffa0099c8970dc2b8bfaaf7
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Treatment of HER2-positive breast cancer: current status and future perspectives (2012, background): “In a phase II clinical trial, treatment with pertuzumab and trastuzumab together resulted in a 24% overall response rate and a 50% clinical benefit rate, in patients with HER2-positive metastatic breast cancer that had previously progressed on trastuzumab”
- Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. (2011, background): “2%) in patients with HER2-positive MBC previously treated with trastuzumab.(23) Other targeted agents are being assessed in combination with trastuzumab for treatment of HER2positive MBC.”